Somatropin (HGH 191AA)

Somatropin is a recombinant human growth hormone identical to the endogenous version, primarily utilized off-label for performance enhancement, muscle gain, and anti-aging, alongside its FDA-approved use for growth hormone deficiency. Community users typically report daily doses of 500 µg, while clinical protocols for conditions like cachexia range from 100 µg to 6 mg administered subcutaneously. Users frequently report changes in sleep quality and vivid dreams, with occasional fluid retention. Readers should note that the evidence base for most exploratory indications remains thin, as many trials lack posted results despite the significant volume of community discussion surrounding the substance.

Half-life~3 h

Data last updated

ClinicalResearchDepthClinicalResearchEfficacyClinicalResearchSideEffectsAnecdotalEfficacyAnecdotalSideEffectsPrice3.64.81.34.04.14.0

Research Evidence

Evidence shape

Somatropin carries a high evidence tier, supported by extensive clinical literature focused on growth hormone deficiency, idiopathic short stature, and HIV-associated visceral fat reduction. With over 200 registered trials and 13 blinded studies, the research base is substantial and spans nearly 100 distinct indications. While the data is robust for established growth disorders, the vast majority of mapped indications remain exploratory or rely on single-trial evidence, indicating that clinical application outside of primary growth-related conditions lacks the same depth of validation.

Depthhow much
207 registered trials
139 completed · 44 with posted results · 23 recruiting / active · combined n=27395
Breadthhow many areas
95 indications mapped
13 with results · 72 thin / exploratory · 1 animal-only · 54 single-trial long-tail
Qualityhow rigorous
Highest tier: Phase 3
13 blinded with results · 63 distinct sponsors · AE rows aggregated from 34 trials · 46 linked publications on registered trials
Breadth and depth219 rows captured
Human
direct clinical signal
212
Animal
translational support
4
In vitro
mechanistic support
3
HighMediumLow

Anecdotal efficacy

Somatropin (HGH 191AA) side effects

Clinical research side effects

Anecdotal side effects

Price

Full buying guide →
1
Fusion X Peptides
GB
1500 mg
$268.45
$0.174/mg
2
Valhalla Biolabs
--
100 mg
$69.99
$0.7/mg
3
peptidesourcehub.com
--
50 mg
$74.90
$1.5/mg
4
Peptalyon CO
--
10 mg
$20.00
$2/mg
5
dutchlabs.eu
--
10 mg
$65.15
$6.52/mg
6
PeptidesSource
USA
5 mg
$35.00
$7/mg

price offers can be sorted by column

1-6 of 12

SOMATROPIN (HGH 191AA) dosing & protocol

How SOMATROPIN (HGH 191AA) is dosed across research, clinician, and community sources — each evidence tier kept separate so the dose range, frequency, timing, and cycling stay visible without flattening different levels of evidence.

Research trials
Published clinical-trial protocols · n = 144
Typical dose
3 mg240 µg – 10 mg
typical
0
2 mg
4 mg
6 mg
8 mg
10 mg
distribution of 23 reported doses · darker = more
Frequency
daily
Route
subQ

In research trials, somatropin is typically given at 3 mg subcutaneously once daily, with reported doses ranging from 240 mcg to 10 mg per day.

144 sources
Clinician practice
Doctor & published-protocol guidance · n = 1
Starting dose
100 µg100 µg – 6 mg
start
0
2 mg
4 mg
6 mg
8 mg
10 mg
distribution of 3 reported doses · darker = more
By reported cadence· tap a row to filter the chart
Frequency
daily
Route
subQ

In clinician practice, the typical dose is 6 mg administered subcutaneously once daily, with reported dosing ranging from 100 µg to 6 mg per day.

1 source
Anecdotal
Community-reported real-world use · n = 1
Typical dose
500 µg
typical
0
2 mg
4 mg
6 mg
8 mg
10 mg
across 1 dosed source · darker = more agree
Frequency
unspecified
Route
subQ

The sole community entry lists 500 mcg subQ, without specifying how often it is taken or any cycling regimen, reflecting only one anecdotal report.

1 source

Regulatory safety notes

Warnings and precautions
  • • Acute Critical Illness: Potential benefit of treatment continuation should be weighed against the potential risk •
  • • Prader-Willi Syndrome in Children: Evaluate for signs of upper airway obstruction and sleep apnea before initiation of treatment Discontinue treatment if these signs occur •
  • • Neoplasm: Monitor patients with preexisting tumors for progression or recurrence. Increased risk of a second neoplasm in childhood cancer survivors treated with somatropin in particular meningiomas in patients treated with radiation to the head for their firs…
  • • Impaired Glucose Tolerance and Diabetes Mellitus: May be unmasked Periodically monitor glucose levels in all patients. Doses of concurrent antihyperglycemic drugs in diabetics may require adjustment •
  • • Intracranial Hypertension: Exclude preexisting papilledema. May develop and is usually reversible after discontinuation or dose reduction •
  • • Hypersensitivity: Serious hypersensitivity reactions may occur. In the event of an allergic reaction, seek prompt medical attention • Fluid Retention (i.e., edema, arthralgia, carpal tunnel syndrome – especially in adults) : May occur frequently. Reduce dose…
  • • Hypoadrenalism: Monitor patients for reduced serum cortisol levels and/or need for glucocorticoid dose increases in those with known hypoadrenalism •
  • • Hypothyroidism: May first become evident or worsen. Monitor thyroid function periodically •
Contraindications
  • • • Acute Critical Illness • Children with Prader-Willi syndrome who are severely obese or have severe respiratory impairment – reports of sudden death • Active Malignancy • Hypersensitivity to somatropin or excipients •…
  • • patients with: • Acute Critical Illness Treatment with pharmacologic amounts of somatropin is contraindicated in
  • • patients with acute critical illness due to complications following open heart surgery, abdominal surgery or multiple accidental trauma, or those with acute respiratory failure [see Warnings and Precautions (5.1) ]. • P…
  • • patients with Prader-Willi syndrome who are severely obese, have a history of upper airway obstruction or sleep apnea, or have severe respiratory impairment. There have been reports of sudden death when somatropin was u…
  • • patients with any evidence of progression or recurrence of an underlying intracranial tumor. • Hypersensitivity GENOTROPIN is contraindicated in
  • • patients with a known hypersensitivity to somatropin or any of its excipients. The 5 mg and 12 mg presentations of GENOTROPIN lyophilized powder contain m-cresol as a preservative. Systemic hypersensitivity reactions ha…
  • • patients with active proliferative or severe non-proliferative diabetic retinopathy. • Closed Epiphyses Somatropin should not be used for growth promotion in pediatric
  • • patients with closed epiphyses.
Drug interactions
  • • Inhibition of 11ß-Hydroxysteroid Dehydrogenase Type 1: May require the initiation of glucocorticoid replacement therapy. Patients treated with glucocorticoid replacement for previously diagnosed hypoadrenalism may require an increase in their maintenance dose…
  • • Replacement: Should be carefully adjusted (7.2) • Cytochrome P450-Metabolized
  • • Drugs: Monitor carefully if used with somatropin (7.3) •
  • • Estrogen: Larger doses of somatropin may be required in women (7.4) •
  • • Agents: May require adjustment (7.5)

Related peptides

CJC-1295IpamorelinMK-677HexarelinGHRP-6GHRP-2SermorelinIpamorelin / CJC-1295 BlendCapromorelin